Table 6.
Characteristics of the clinical practice guidelines (CPGs) on COVID-19.
| Characteristic | Number () | Percentage (%) | |
|---|---|---|---|
| Publication month | Jan | 1 | 1.1 |
| Feb | 7 | 7.6 | |
| Mar | 19 | 20.7 | |
| Apr | 16 | 17.4 | |
| May | 9 | 9.8 | |
| Jun | 6 | 6.5 | |
| Jul | 4 | 4.3 | |
| Aug | 1 | 1.1 | |
| Sep | 9 | 9.8 | |
| Oct | 3 | 3.3 | |
| Nov | 9 | 9.8 | |
| Dec | 8 | 8.6 | |
|
| |||
| Publication country/organization | China | 29 | 31.5 |
| USA | 19 | 20.7 | |
| International cooperation (other than WHO) | 7 | 7.6 | |
| UK | 4 | 4.3 | |
| Canada | 4 | 4.3 | |
| Australia | 4 | 4.3 | |
| WHO | 6 | 6.5 | |
| India | 3 | 3.3 | |
| South Korea | 3 | 3.3 | |
| Netherlands | 2 | 2.2 | |
| Ireland | 2 | 2.2 | |
| Germany | 2 | 2.2 | |
| Turkey | 1 | 1.1 | |
| Switzerland | 1 | 1.1 | |
| Spain | 1 | 1.1 | |
| Poland | 1 | 1.1 | |
| Mexico | 1 | 1.1 | |
| Italy | 1 | 1.1 | |
| Brazil | 1 | 1.1 | |
|
| |||
| Version of CPGs | Original | 62 | 67.4 |
| Updated | 30 | 32.6 | |
|
| |||
| Interim CPGs | Yes | 18 | 19.6 |
| No | 74 | 80.4 | |
|
| |||
| Publication format | Journal | 60 | 65.2 |
| Website only | 32 | 34.8 | |
|
| |||
| Developer | Society/association * | 42 | 45.2 |
| University | 15 | 16.1 | |
| National institution/council | 10 | 10.8 | |
| Hospital | 12 | 12.9 | |
| WHO | 6 | 6.5 | |
| National Centers for Disease Control (CDC) * | 6 | 6.5 | |
| Not mentioned | 2 | 2.2 | |
|
| |||
| Rating system for the quality of evidence and strength of recommendations | GRADE system | 20 | 21.7 |
| Other systems | 5 | 5.4 | |
| Not reported | 67 | 72.8 | |
|
| |||
| Methods to reach consensus | Reported | 26 | 28.3 |
| Not reported | 66 | 71.7 | |
|
| |||
| Funding | Reported funding | 17 | 18.5 |
| Reported explicitly not to have received funding | 17 | 18.5 | |
| Not reported | 58 | 63.0 | |
|
| |||
| Management of conflicts of interest | Yes | 20 | 21.7 |
| No | 36 | 39.1 | |
| Not reported | 36 | 39.1 | |
*One CPG that was codeveloped by a CDC and a society.